BCL2 and lymphoma: Here we demonstrate that targeting Bcl-2 with the more selective inhibitor, ABT-199, is sufficient to synergize with eIF4A inhibition mediated by CMLD011580 in the triple-hit lymphoma cell line, SC-1.